Loading...
Market
Which company will partner with PTC Therapeutics for Kebilidi by June 30, 2025?
3
Resolution / Starting Odds
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Press releases from PTC Therapeutics or announcements from partner companies
Story
PTC Therapeutics' Kebilidi Gene Therapy for AADC Deficiency Gains FDA Approval, Stock Up 3.3%
Nov 14, 2024, 01:23 PM
PTC Therapeutics has received FDA approval for its gene therapy targeting aromatic L-amino acid decarboxylase (AADC) deficiency, an ultra-rare and fatal enzyme disorder. The therapy, named Kebilidi, is the first of its kind approved for treating both adult and pediatric patients with this condition. Following the announcement, PTC Therapeutics' stock price rose by 3.3% in pre-market trading.
View original story
Similar markets
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Roche • 25%
Pfizer • 25%
AstraZeneca • 25%
No new partnership • 25%
Pfizer • 25%
Novartis • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Wave Life Sciences • 25%
CRISPR Therapeutics • 25%
Moderna • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
